Arkolith/Insider Trading/CARA/Form 4

Reilly Thomas Charles

Chief Financial OfficerCara Therapeutics, Inc. (CARA) · full profile →Form 4 · filed Mar 1, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 28, 2022Grant(A)5K$10.29$55K40K
Feb 25, 2022Grant(A)20K—$035K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 25, 2022Grant(A)40K—$040K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001209191-22-013992) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML